Ftse Mib
34.657,35
0,93%
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
NASDAQ
16.340,87
-0,03%
Bitcoin
61.079,51
0,47%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MannKind Corporation (MNKD) MannKind Corporation (MNKD) Notizie

MNKD

MannKind (MNKD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNKD
DataOraFonteTitoloSimboloCompagnia
08/05/202422:18GlobeNewswire Inc.MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
08/05/202422:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNKDMannKind Corporation
08/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
06/05/202412:05GlobeNewswire Inc.MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
01/05/202422:00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
30/04/202412:05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
29/04/202412:05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
03/04/202412:00GlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
26/03/202421:05GlobeNewswire Inc.MannKind Announces CFO TransitionNASDAQ:MNKDMannKind Corporation
11/03/202411:05GlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsNASDAQ:MNKDMannKind Corporation
05/03/202412:05GlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8NASDAQ:MNKDMannKind Corporation
04/03/202419:01GlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
27/02/202422:00GlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
20/02/202412:00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024NASDAQ:MNKDMannKind Corporation
15/02/202412:05GlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®NASDAQ:MNKDMannKind Corporation
05/02/202412:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/01/202412:05GlobeNewswire Inc.MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionNASDAQ:MNKDMannKind Corporation
28/12/202312:00GlobeNewswire Inc.MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
15/12/202322:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
07/11/202322:00GlobeNewswire Inc.MannKind Corporation Reports 2023 Third Quarter Financial ResultsNASDAQ:MNKDMannKind Corporation
06/11/202312:15GlobeNewswire Inc.MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 DiabetesNASDAQ:MNKDMannKind Corporation
31/10/202321:00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023NASDAQ:MNKDMannKind Corporation
30/10/202311:15GlobeNewswire Inc.MannKind Expands Patent Portfolio With New Clofazimine Formulation PatentNASDAQ:MNKDMannKind Corporation
04/10/202303:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:MNKDMannKind Corporation
23/08/202322:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MNKDMannKind Corporation
07/08/202322:00GlobeNewswire Inc.MannKind Corporation Reports 2023 Second Quarter Financial ResultsNASDAQ:MNKDMannKind Corporation
01/08/202312:00GlobeNewswire Inc.MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
31/07/202322:00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023NASDAQ:MNKDMannKind Corporation
22/06/202312:05GlobeNewswire Inc.MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)NASDAQ:MNKDMannKind Corporation
11/06/202314:05GlobeNewswire Inc.Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing MilestoneNASDAQ:MNKDMannKind Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNKD

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
BFF
BFF Bank
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
IVG
Iveco Group NV
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
NEXI
Nexi S.p.A
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
MB
Mediobanca Banca di Cred...
BIT
PRY
Prysmian
BIT
STMMI
ST Microelectronics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network